Product image of Methofill (Methotrexate) supplied by GNH India

Methofill

Active Ingredient:
Methotrexate
Origin:
EU

Methofill (Methotrexate)

Methotrexate, the active ingredient in Methofill, is an antimetabolite (folate antagonist) presented as an intravenous solution for intravenous use. It is employed in the management of certain cancers, autoimmune disorders, and ectopic pregnancy in adult patients.

GNH India supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring quality and regulatory compliance.

Manufacturer / TM Owner

Accord Healthcare B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families.

  • Rheumatoid arthritis: reduces joint inflammation and slows structural damage.
  • Psoriasis: diminishes skin plaque formation and severity.
  • Acute lymphoblastic leukemia: interferes with malignant cell proliferation.
  • Non‑Hodgkin lymphoma: impedes growth of lymphoma cells.
  • Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

How It Works

  • Methotrexate inhibits dihydrofolate reductase, preventing the regeneration of tetrahydrofolate required for purine and pyrimidine synthesis. This blockade reduces DNA, RNA, and protein production, leading to cytotoxic effects on rapidly dividing cells and modulation of immune cell activity, which underlies its antineoplastic and anti‑inflammatory actions.

Side Effects

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset occurring shortly after infusion.
  • Mucositis: inflammation and ulceration of the oral mucosa.
  • Fatigue: generalized tiredness during treatment cycles.
  • Elevated liver enzymes: mild transaminase rise detected on labs.
  • Myelosuppression: reduced white blood cell and platelet counts.
  • Dermatologic rash: mild skin irritation or erythema.

Serious or Rare Side Effects

  • Pulmonary toxicity: interstitial pneumonitis presenting with cough and dyspnea.
  • Severe hepatotoxicity: marked liver injury requiring monitoring.
  • Renal failure: acute kidney injury due to precipitation of drug crystals.
  • Severe bone marrow suppression: pancytopenia with infection risk.
  • Neurotoxicity: seizures or encephalopathy in high‑dose settings.
  • Anaphylaxis: rare hypersensitivity reaction requiring immediate medical attention.

Precautions & Warnings

Methofill requires careful monitoring and patient education before and during therapy.

  • Pregnancy: contraindicated; teratogenic risk is classified as Category X.
  • Renal function: assess creatinine clearance; dose adjustment may be needed.
  • Hepatic function: monitor liver enzymes regularly; avoid in severe hepatic impairment.
  • Hematologic status: perform complete blood counts before each dose.
  • Concomitant folate: supplement with folic acid to reduce mucosal toxicity.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methofill can interact with several drug classes, altering efficacy or toxicity.

Major Interactions (Avoid)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity.
  • Proton pump inhibitors: may elevate methotrexate serum levels.
  • Penicillins (high‑dose): reduce renal clearance, raising toxicity risk.

Moderate Interactions (Monitor Closely)

  • Sulfonamides: additive bone‑marrow suppression.
  • Azathioprine or mycophenolate: enhanced immunosuppression.
  • Live vaccines: risk of infection due to immunosuppression.
  • Trimethoprim‑sulfamethoxazole: increased myelosuppression.
  • Vitamin B12 or folic acid supplements: may lessen therapeutic effect if excessive.

Frequently Asked Questions

Methofill, containing methotrexate, is prescribed for rheumatoid arthritis, moderate to severe plaque psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma, and medically managed ectopic pregnancy. It works by targeting rapidly dividing cells and modulating immune responses, providing disease control across these indications.

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folic acid into its active form. This inhibition disrupts DNA, RNA, and protein synthesis in rapidly dividing cells, leading to anti‑cancer effects and suppression of abnormal immune activity in autoimmune diseases.

The specific dose of Methofill is determined by the prescribing clinician based on the patient’s condition, disease severity, renal and hepatic function, and other individual factors. Healthcare providers set the appropriate dosing regimen and monitor response throughout treatment.

Methofill is classified as Pregnancy Category X because it is known to cause fetal harm and is contraindicated in pregnancy. It is also not recommended during breastfeeding, as methotrexate can be excreted in breast milk and may affect the infant.

To request Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Methofill (methotrexate) is a folate antagonist that offers both immunomodulatory and cytotoxic effects, making it useful for autoimmune diseases and certain cancers. Compared with biologic DMARDs, it is less expensive but may require more laboratory monitoring. Against other chemotherapy agents, it has a broad spectrum of activity but a distinct toxicity profile that includes hepatic and pulmonary risks.

Methofill should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken vigorously. Keep the vial in its original packaging until ready for use to maintain stability.

Methofill is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a short infusion period, following institutional protocols and patient monitoring guidelines.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity with potential liver failure, pulmonary toxicity such as interstitial pneumonitis, and renal failure. Prompt recognition of symptoms and regular laboratory monitoring are essential to mitigate these risks.

Methofill is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, and those with active, uncontrolled infections. Caution is also advised for patients with pre‑existing lung disease or a history of severe myelosuppression.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT